Table 3.
Variables Affecting Cataract and/or Dry Eye Syndrome Development
| Cataract | Dry Eye | |||||
|---|---|---|---|---|---|---|
| Variable | HRa | 95% CI | Pb | HR | 95% CI | P |
| Age at Transplantation | 0.9 | 0.8361–0.9654 | 0.0035 | 1.2 | 1.074–1.267 | 0.00026 |
| Age at Cancer Diagnosis | 0.96 | 0.9185–0.9992 | 0.046 | 1 | 0.9803–1.106 | 0.19 |
| Dose of Total Body Irradiation | 1 | 1.001–1.002 | <0.001 | 1 | 0.9989–0.9998 | 0.0029 |
| Dose of Head/Neck Radiation | 1 | 0.9998–1.001 | 0.33 | 1 | 0.9996–1.001 | 0.51 |
| Dose of Non-Head/Neck Radiation | 1 | 0.9996–1.001 | 0.28 | 1 | 0.9994–1.001 | 0.68 |
| Gender: Male | 1.3 | 0.7797–2.257 | 0.3 | 0.94 | 0.5491–1.609 | 0.82 |
| Race: Other | 3.5 | 0.9293–13.1 | 0.064 | 0.96 | 0.4574–2.009 | 0.91 |
| Race: White | 4.9 | 1.556–15.43 | 0.0066 | 0.75 | 0.3716–1.507 | 0.42 |
| Nonmalignant Disease | 0.19 | 0.06523–0.5448 | 0.0021 | 1.3 | 0.6975–2.325 | 0.43 |
| Sibling Donor | 1.2 | 0.492–3.044 | 0.66 | 0.52 | 0.2486–1.097 | 0.086 |
| Unrelated Donor | 2.3 | 0.9423–5.406 | 0.068 | 0.34 | 0.1492–0.789 | 0.012 |
| Survival: Deceased | 0.95 | 0.3017–2.998 | 0.93 | 1.2 | 0.3684–3.941 | 0.76 |
| Product Type: Cord blood | 7.00E-05 | 1.45E-05–0.000337 | 0 | 0.93 | 0.08214–10.61 | 0.96 |
| Product Type: Marrow | 1.8 | 0.796–3.881 | 0.16 | 0.35 | 0.1967–0.6276 | 0.00041 |
| Cytomegalovirus-Positive Recipient | 0.45 | 0.2632–0.7828 | 0.0045 | 1.1 | 0.6348–1.906 | 0.73 |
| Steroid Use | 0.61 | 0.3065–1.215 | 0.16 | 3.5 | 1.974–6.132 | <0.001 |
| Calcineurin Inhibitor Use | 1.2 | 0.4844–2.78 | 0.74 | 1.3 | 0.5418–3.256 | 0.53 |
| Acute Graft-versus-Host Disease | 0.83 | 0.4841–1.412 | 0.49 | 1.6 | 0.9487–2.826 | 0.077 |
| Chronic Graft-versus-Host Disease | 0.72 | 0.3537–1.469 | 0.37 | 3.5 | 2.045–5.967 | <0.001 |
| Total Body Irradiation | 5.6 | 2.302–13.41 | 0.00014 | 0.48 | 0.2723–0.8371 | 0.0099 |
| Busulfan Use | 0.6 | 0.1993–1.797 | 0.36 | 1.2 | 0.6129–2.416 | 0.57 |
| Cyclophosphamide Use | 2.5 | 0.8398–7.18 | 0.1 | 0.28 | 0.1388–0.5851 | 0.00063 |
| Cytarabine Use | 3 | 1.812–5.045 | <0.001 | 0.25 | 0.1346–0.4694 | <0.001 |
| Fludarabine Use | 0.26 | 0.07598–0.8755 | 0.03 | 3.4 | 1.777–6.539 | 0.00023 |
| Melphalan Use | 0.26 | 0.05969–1.148 | 0.076 | 7.2 | 3.526–14.58 | <0.001 |
| Thiotepa Use | 0.68 | 0.3813–1.206 | 0.19 | 3 | 1.681–5.477 | 0.00023 |
| Conditioning Treatment: Chemotherapy only | 0.1 | 0.01379–0.7778 | 0.028 | 0.99 | 0.3716–2.643 | 0.99 |
| Conditioning Treatment: None | 0.21 | 0.08074–0.5519 | 0.0015 | 2.9 | 1.573–5.468 | 0.00071 |
Abbreviations: CI, confidence interval; HR, hazard ratio
Statistically significant values are in bold.